Puma Biotechnology (PBYI) Competitors

ADMA Biologics (NASDAQ:ADMA) and Puma Biotechnology (NASDAQ:PBYI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Which has preferable earnings and valuation, ADMA or PBYI?

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$426.45M	9.01	$197.67M	$0.86	18.73
Puma Biotechnology	$230.50M	0.98	$30.28M	$0.98	4.56

Is ADMA or PBYI more profitable?

ADMA Biologics has a net margin of 44.06% compared to Puma Biotechnology's net margin of 20.38%. Puma Biotechnology's return on equity of 53.15% beat ADMA Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	44.06%	41.01%	28.47%
Puma Biotechnology	20.38%	53.15%	23.51%

Do institutionals and insiders believe in ADMA or PBYI?

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 3.5% of ADMA Biologics shares are held by insiders. Comparatively, 23.3% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media prefer ADMA or PBYI?

In the previous week, Puma Biotechnology had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 3 mentions for Puma Biotechnology and 2 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.43 beat Puma Biotechnology's score of 1.40 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Puma Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ADMA or PBYI?

ADMA Biologics presently has a consensus price target of $27.67, indicating a potential upside of 71.74%. Puma Biotechnology has a consensus price target of $7.00, indicating a potential upside of 56.60%. Given ADMA Biologics' stronger consensus rating and higher probable upside, equities research analysts plainly believe ADMA Biologics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Puma Biotechnology	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, ADMA or PBYI?

ADMA Biologics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Summary

ADMA Biologics beats Puma Biotechnology on 12 of the 17 factors compared between the two stocks.